&nbsp;

OBSP-8-12-20.html

Dec 2020

Document

OntarioCancerProfilesSurvival.xlsx

Dec 2020

Document

OntarioCancerScreeningReport2020.pdf

Jan 2021

Document

OPNPReferralForm.docx

Jan 2021

Document

obsp-15-1-21.xml

Jan 2021

Document

OBSP-15-1-21.html

Jan 2021

Document

obsp-22-1-21.xml

Jan 2021

Document

OBSP-22-1-21.html

Jan 2021

Document

obsp-18-2-21.xml

Feb 2021

Document

OBSP-18-2-21.html

Feb 2021

Regimen

OLAP

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

olaparib - For the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria

, Collapse Show fewer tags

Drugs Used:

olaparib

... Show more tags

Quick Link(s):

Regimen Monograph

Dec 2024

Regimen

PEMB

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer